years (RRR = 1.47, 95% CI 1.00-2.16), age ≥ 70 years (RRR = 2.24, 95% CI 1.57-3.20), and male sex (RRR = 1.73, 95% CI 1.32-2.27) were positively associated with proximal only adenoma recurrence. NSAIDs use was associated with a reduced risk of adenoma recurrence by similar magnitude in distal (RRR = 0.78, 95% CI 0.58-1.07) and proximal colon (RRR = 0.77, 95% CI 0.60-1.00). Conclusions: We did not find any modifiable risk factor that differentially increases proximal as compared to distal adenoma recurrence to be clinically useful for targeted intervention.
screening colonoscopy, the reported differences in the effectiveness of colonoscopy in proximal versus distal colon are compelling.
Explanations of why endoscopic effectiveness may be reduced in the proximal colon include that colonoscopy visualization may be worse in the proximal colon due to poor bowel preparation, that there is less adequate examination by endoscopists in the proximal colon, and that there is less adequate detection of flat and depressed lesions in the proximal colon [8] . However, it is also possible that the biology of colon cancer differs by tumor location. Evidence from laboratory and genetic studies suggests that proximal and distal colon cancers have distinct gene-specific methylation profiles and molecular characteristics [9, 10] .
It is unknown whether risk factors associated with adenoma recurrence also exhibit proximal versus distal colon differences in their associations. Identification of factors that differentially increase the risk of proximal as compared to distal adenoma recurrence can potentially guide a clinically useful risk stratification scheme. In this secondary analysis of the comprehensive information on adenoma location from the Polyp Prevention Trial (PPT), we examined whether demographic and lifestyle factors are differentially associated with proximal and distal adenoma recurrence.
Methods

Study Population
The details of the rationale, design, and results of the PPT have been described in previous publications [11] [12] [13] . In brief, the PPT was a 4-year multicenter, randomized, controlled trial designed to assess the effect of a low-fat, high-fiber diet on the risk of recurrence of adenomatous polyps. The study involved 2,079 participants who were at least 35 years of age and had one or more histologically confirmed adenomatous polyp removed within 6 months before randomization. The participants had no previous history of surgical resection of adenomatous polyps, bowel resection, colorectal carcinoma, polyposis syndrome, or inflammatory bowel disease. The clinical trial was approved by the Institutional Review Boards of the National Cancer Institute and each of the eight participating clinical centers. All participants gave written informed consent. A total of 1,905 (91.6%) participants completed the trial and underwent colonoscopy four years after randomization. The trial took place from 1991 to 1998. The dietary intervention did not affect adenoma recurrence [13] . For the present study, our analytic cohort included 1,864 participants for whom we had complete information on the location of their adenoma.
Exposure Assessment
At baseline, information on the participant's demographic characteristics, health-related lifestyle, and medication use was obtained through direct interview. For this study, we examined age, sex, BMI, smoking status, and use of nonsteroidal anti-inflammatory drugs (NSAIDs) at least once a month.
Outcome Assessment
The participants underwent a clearing colonoscopy approximately 1 year after randomization (T1) to remove any missed lesion at qualifying colonoscopy (T0). They were followed for approximately 4 years after randomization, and had follow-up colonoscopy at the end of the trial (T4). Adenomas found at the T4 colonoscopy were the primary outcome. The colonoscopy reports provided information on size, number, and location of polyps. The histology and degree of atypia were confirmed by two trial pathologists. The location of adenomas removed from the rectum to the splenic flexure was defined as distal, while proximal location included the transverse colon to the cecum. We defined an advanced adenoma as adenoma with size ≥ 1 cm in diameter, or villous histology or high grade dysplasia.
Statistical Analyses
We used multinomial logistic regression analyses to evaluate the association of baseline characteristics and lifestyle factors with subsequent adenoma recurrence at the end of the trial as our primary analysis. This was to determine the specific risk estimates associated with the colon subsites. We classified adenoma recurrence into 4 mutually exclusive groups according to findings at the end of trial colonoscopy (T4): those without any adenoma recurrence (comparison group); those with distal only; those with proximal only; and those with synchronous (both) distal and proximal adenoma recurrence.
We classified advanced adenoma outcome into 3 mutually exclusive groups: those without any adenoma recurrence (comparison group), those with only distal advanced adenoma recurrence, and those with any proximal advanced adenoma recurrence (this includes those with proximal advanced adenomas only and those with both distal and proximal advanced adenoma recurrence, because few participants had synchronous advanced adenomas in the distal and proximal colon, n = 12). We conducted a sensitivity analysis in which we added the recurrent synchronous distal and proximal advanced adenomas (n = 12) to the distal only advanced adenoma group and found similar results (data not shown).
We have previously reported that patients with proximal adenoma had increased risk of advanced adenoma recurrence [14] and that proximal adenoma at baseline was associated with proximal adenoma at recurrence [15] . Therefore, we included the baseline location of adenoma in all the multivariable models. Although, the colonoscopy performed one year after randomization (T1) was regarded as a clearing colonoscopy to remove potentially missed lesions, we repeated our analysis and added adenomas found at T1 to the end-of-trial colonoscopic findings in a sensitivity analysis.
In a comparative analysis, we also used Poisson regression models to compare the risk factors associated with proximal adenoma and advanced adenoma recurrence and used distal adenoma and advanced adenoma recurrence as the comparison group. We used Stata ® statistical software version 11.2 (College Station, Tex., USA) for all analyses. All reported p values correspond to twosided tests. Table 1 shows the baseline characteristics of the study participants. The mean age was 61.1 years, 64.3% male, 73.5% were overweight or obese and 61% had a history of smoking.
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Results
Baseline Characteristics
Adenoma Recurrence by Location
At follow-up colonoscopy, 1,131 (60.7%) participants had no recurrence while 733 (39.3%) had adenoma recurrence. Of these, 228 (31.1%) participants had distal only, 369 (50.3%) had proximal only and 136 (18.6%) had synchronous distal and proximal adenoma recurrence ( table 2 ). When compared to participants without adenoma recurrence, no factor was a significant independent risk factor for distal only adenoma recurrence. However, we noted that when compared to participants who were younger than 55 years, those age 65-69 years (relative risk ratio (RRR) = 1.47, 95% CI 1.00-2.16), and age ≥ 70 years (RRR = 2.24, 95% CI 1.57-3.20) were positively associated with proximal only recurrence, as well as male sex (RRR = 1.73, 95% CI 1.32-2.27). The use of NSAIDs had borderline reduced association (RRR = 0.77, 95% CI 0.60-1.00).
We also observed statistically increased risk of synchronous distal and proximal adenoma recurrence in association with advancing age, male sex and obesity (BMI ≥ 30) ( table 2 ). In contrast, NSAIDs use was associated with a borderline reduction in distal only (RRR = 0.78, 95% CI 0.58-1.07), proximal only (RRR = 0.77, 95% CI 0.60-1.00) and synchronous distal and proximal (RRR = 0.76, 95% CI 0.51-1.12) adenoma recurrence.
Advanced Adenoma Recurrence by Location
A total of 119 participants had advanced adenoma recurrence (47 distal only, 60 proximal only and 12 synchronous proximal and distal). No factor was associated with an increased risk of distal only advanced adenoma recurrence whereas advancing age showed a trend towards increased risk of a proximal advanced adenoma, which became statistically significant for participants who were 60 years and older ( table 3 ) . The risk of advanced adenoma recurrence was reduced by >50% in both colon subsites by the use of NSAIDs.
When we restricted our analysis to the subset of patients with distal only and proximal only adenoma and advanced adenoma recurrence, only male sex was associated with an increased risk of proximal only adenoma recurrence when compared to distal only adenoma recurrence (RR = 1.18, 95% CI 1.02-1.38) and advancing age was associated with an increased risk of proximal advanced adenoma recurrence ( table 4 ) .
Sensitivity Analysis
When we added the adenoma removed at colonoscopy performed 1 year after randomization (T1) to the end-oftrial findings (T4), the results were similar except that we observed that male sex became associated with a statistically significant risk of distal adenoma recurrence (RRR = 1.43, 95% CI 1.07-1.92) and distal advanced adenoma recurrence (RRR = 1.76, 95% CI 1.04-3.00). The risk of synchronous distal and proximal adenoma recurrence also became significant for BMI 25-29 (RRR = 1.48, 95% CI 1.03-2.13) and current cigarette smoking (RRR = 1.76, 95% CI 1.16-2.68).
Discussion
Although three randomized control trials of screening colonoscopy are currently underway (http://www.clinicaltrials.gov; identifiers NCT00906997, NCT01239082, and NCT00883792), the results are not expected until at Meanwhile, recent population-based reports of lower efficacy of colonoscopy in reducing colon cancer incidence and mortality in proximal versus distal colon [3] [4] [5] [6] make it important to investigate factors associated with this findings so that targeted interventions can be developed and implemented. Therefore, we evaluated whether known risk factors for adenoma recurrence increase proximal versus distal adenoma recurrence. Only male sex and advancing age were associated with proximal only adenoma recurrence and these are nonmodifiable risk factors.
Our findings corroborate the suggestion that cancer prevention in the proximal colon may be quite challenging. The risk factors that have been associated with adenoma recurrence may not be useful for identifying those at a higher risk for proximal colon cancer for targeted intervention. This makes it imperative to perform high quality screening and surveillance colonoscopy. Future studies should also evaluate other approaches including the use of biomarkers.
Only obesity has been studied previously with respect to distal and proximal adenoma recurrence. Jacobs et al. [16] reported an increased odds of proximal adenoma recurrence (OR = 1.34, 95% CI 1.15-1.57) for obese patients (BMI ≥ 30), but there was no association with distal adenoma recurrence (OR = 1.02, 95% CI 0.81-1.27). Other studies have evaluated risk factors for proximal and distal colon cancer. Using the Illinois tumor registry, Nelson et al. [17] reported that age and male sex were independently associated with both proximal and distal colon cancer risk. They also reported that males had higher odds of both proximal and distal colon cancer. In another study, Gonzalez et al. [18] analyzed the incident cases of colon cancer from Florida's statewide cancer registry and reported that increasing age, female sex and the presence of comorbid illnesses were associated with increased odds of proximal colon cancer. The report that age had a greater effect on proximal than distal colon cancer risk mirrors our findings of increased susceptibility to proximal adenoma recurrence with increasing age.
The use of NSAIDs has been shown to be inversely associated with the risk of adenoma recurrence in randomized control trials [19] [20] [21] . However, these studies did not evaluate the possibility of a differential protective effect by colon subsite. A reduction in colorectal cancer incidence has also been demonstrated with NSAIDs in cohort studies [22, 23] . Among participants in the Nurses' Health Study, Chan et al. [22] reported a reduced risk of incident distal (RRR = 0.64, 95% CI 0.51 to 0.81) and proximal (RRR = 0.77, 95% CI 0.62-0.94) colon cancer among regular users (2 or more standard 325 mg aspirin tablets per week). In a population-based retrospective cohort study, Smalley et al. [23] reported a reduced risk of colon cancer among recent users of NSAIDs with more than 12 months of cumulative use (RRR = 0.77, 95% CI 0.55-1.08 for distal and RRR = 0.48, 95% CI 0.34-0.68 for proximal cancer). In our study, use of NSAIDs (at least once a month) was associated with approximately 50% decreased risk of advanced adenoma in both the proximal and distal colon. Cardiac side effects observed in chemoprevention trials of cyclooxygenase-2 inhibitors [19] [20] [21] have precluded their recommendation as a chemoprevention strategy [24] , and bleeding risk limits nonselective NSAIDs use. Developing chemopreventive agents with an acceptable riskbenefit ratio remains a goal.
There are many strengths of our study. Although, our study end point was not prespecified as part of the original PPT, the trial's comprehensive information on adenoma location provided an opportunity to compare distal and proximal adenoma recurrence. PPT was a large randomized controlled trial with participants recruited from geographically dispersed areas, informa- tion on candidate risk factors was prospectively gathered, all patients had planned colonoscopic assessment for recurrence after an adequate follow-up period, and dedicated trial pathologists with expertise in gastrointestinal tumors examined the adenomas, thereby ensuring consistency. However, our study has limitations. The participants in the PPT were self-selected and may be healthier than comparable members of the general population. Also, we could not assess the effect of serrated polyps, flat, and depressed lesions in our study because they were not widely discussed at the time the trial was conducted.
In conclusion, no modifiable risk factor for adenoma recurrence affect proximal versus distal adenoma recurrence differently to offer clinically useful guide for cancer prevention in the proximal colon. Further studies geared towards identifying individuals at a higher risk of metachronous proximal colon neoplasia are needed.
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